June 16, 2011 (Washington, DC) — Several new studies highlight the efficacy of treatments for migraine, including orally inhaled dihydroergotamine, weight-based rizatriptan in pediatric patients, and ...

YARDLEY, Pa., Oct. 2, 2012 /PRNewswire/ -- OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered ...

SAN FRANCISCO — The sumatriptan 3-mg subcutaneous auto-injector (Zembrace SymTouch, Promius Pharma) approved by the US Food and Drug Administration (FDA) for acute treatment of episodic migraine, with ...

Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System SAN DIEGO, July 16 ...

Subcutaneous sumatriptan 6 mg is undeniably an excellent treatment of migraine. However, some patients have avoided using 6 mg sumatriptan because of unpleasant or unwanted side effects. To evaluate ...

A study of the four different routes of administration of sumatriptan shows that the way the drug is given can impact how quickly and effectively a patient will receive migraine relief. In this review ...

SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders ...

Zogenix to Present New Case Study Highlighting Successful Repositioning of Injectable Sumatriptan for Migraine With a Novel Needle-Free Delivery Technology Presentation at the 2nd Annual Drug ...

Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...

SAN DIEGO, May 18, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it presented three posters highlighting its proprietary DosePro ® Needle-free Delivery System (DosePro) at ...